About Moderna
Moderna is a biotechnology company headquartered in Cambridge, Massachusetts, pioneering messenger RNA (mRNA) medicines and vaccines, with commercial manufacturing in Norwood, Massachusetts.
Milestones
Milestones as listed on modernatx.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on modernatx.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Products & Services
Products and services as listed on modernatx.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
mCOMBRIAX
Combination flu plus COVID-19 vaccine approved in the EU in 2026.
Source: modernatx.comPipeline & Regulatory Record
What public registers list for Moderna: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 6 Oct 2026.
Recent approvals
- mCombriaxEMA · influenza mRNA vaccine;COVID-19 mRNA vaccine · 20 Apr 2026
- mNexspikeEMA · COVID-19 mRNA vaccine · 12 Feb 2026
Group (Moderna): founded 2016, headquarters Cambridge, website modernatx.com. Wikidata Q17081612 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.
How this is matched: register records are linked to this page by the organisation name they carry, here Moderna Inc.; Moderna Biotech Spain S.L.; MODERNA BIOTECH SPAIN, S.L (Non-Current); Moderna Biotech Spain, S.L.. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports Moderna, Inc. files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $1.94bn | $3.13bn | 161.1% | −$2.82bn | 10-K 2026 |
| Dec 2024 | $3.24bn | $4.54bn | 140.4% | −$3.56bn | 10-K 2026 |
| Dec 2023 | $6.85bn | $4.85bn | 70.8% | −$4.71bn | 10-K 2026 |
| Dec 2022 | $19.26bn | $3.30bn | 17.1% | $8.36bn | 10-K 2023 |
| Dec 2021 | $18.47bn | $1.99bn | 10.8% | $12.20bn | 10-K 2023 |
Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.